微波消融联合TACE治疗结肠癌肝转移  

Combination of percutaneous microwave coagulation therapy with TACE for treatment of colorectal liver metastases

作　　者：张崇高[1] 王国林[1] 穆四清[1] 

机构地区：[1]江苏省金湖县人民医院放射科,江苏金湖211600

出　　处：《中国介入影像与治疗学》2012年第6期415-418,共4页Chinese Journal of Interventional Imaging and Therapy

摘　　要：目的评价微波消融治疗(PMCT)联合TACE治疗结肠癌肝转移的疗效。方法对18例结肠癌肝转移患者先行TACE,20～25天后再行PMCT,观察TACE联合PMCT治疗结肠癌肝转移前、后肿瘤坏死、CEA水平变化、生存期及不良反应。结果术后3个月,肿瘤完全坏死率83.33%(15/18);15例(15/18,83.33%)患者CEA明显降低;1、2、3年生存率分别为88.89%(16/18)、72.22%(13/18)、50.00%(9/18)。结论 PMCT联合TACE治疗结肠癌肝转移安全、有效。Objective To assess the treatment efficacy of percutaneous microwave coagulation therapy （PMCT） combined with TACE for treatment of liver metastases in patients with colorectal liver metastases （CRLM）. Methods TACE was performed in 18 patients with CRLM, and PMCT was performed after 20--25 days. Tumor necrosis, pre- and post-opera- tive CEA level, life span and adverse reaction were observed. Results The following up showed the complete necrosis rate of the tumor was 83.33% （15/18） 3 months after procedure. Significant reduction of CEA was presented in 83.33% （15/ 18） of the patients. The 1-, 2- and 3-year survival rate was 88.89% （16/18）, 72.22% （13/18） and 50.00% （9/18）, re- spectively. Conclusion PMCT combined with TACE is effective and safe for treating CRLM.

关 键 词：结肠肿瘤 肿瘤转移 肝肿瘤 微波 化学栓塞 治疗性 

分 类 号：R735.7[医药卫生—肿瘤]